[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,45,0,25,[9,43,64,93,120,162,187,215,243,269,304,325,353,377,401,426,456,483,514,546,572,593,617,651,710],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100538456","phase-4-comparison-of-the-effects-of-belatacept-and-anticalcineurins-on-endothelial-function-in-renal-transplant-patients---belafendo-100538456",false,"NCT06291077","Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - \u003CBELAFENDO>","Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients \u003CBELAFENDO>","BELAFENDO","Inclusion Criteria:\n\nFor the Belatacept group:\n\n\\- Patients who have undergone a graft biopsy due to impaired renal function finding criteria for chronic toxicity of anticalcineurins leading to the introduction of Belatacept.\n\nFor the anticalcineurin group:\n\n* Renal transplant patients treated with anticalcineurins for more than a year.\n* Stable renal function (defined by a creatinine level in µmol\u002Fl stable for 3 months (variation +\u002F-20%)\n\nFor both groups:\n\n* Date of kidney transplant greater than 1 year\n* Age between 18 and 75 years inclusive\n* Patient having received clear information from one of the investigators, having read and understood the information letter and signed the consent form\n* Women :\n\n  * of childbearing age (defined by the CTFG as a fertile woman, after menarche and until menopause, except in cases of permanent sterility (including hysterectomy, bilateral salpingectomy or bilateral oophorectomy)\n\n    * using effective contraception according to the WHO (combined hormonal contraception (containing estrogens and progestins), progestin-only contraception, intrauterine device (IUD), male or female condoms) for at least 4 weeks before inclusion and during the study And,\n    * presenting a negative urine pregnancy test at inclusion;\n  * menopausal: menopause according to the CTFG is defined as the absence of periods for 12 months without any other medical cause. An elevated follicle-stimulating hormone (FSH) level in the postmenopausal interval can be used to confirm a postmenopausal state in women who are not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n* Patient benefiting from a social protection scheme\n\nExclusion Criteria:\n\n* Stage 5 chronic renal failure (defined by a CKD-EPI GFR\\\u003C15 ml\u002Fmin\u002F1.73m²)\n* Dialysis patient\n* History of myocardial infarction or stroke less than 6 months old\n* Systolic heart failure requiring hospitalization in the 6 months preceding inclusion or known heart failure with an LVEF \\\u003C30%\n* BMI\\>35 kg\u002Fm²\n* Severe hepatic insufficiency (Child-Pugh class C)\n* Contraindication to NATISPRAY 0.30 mg\u002Fdose, solution for oral spray (and in particular hypersensitivity to nitrates in accordance with the SPC (Summary of Product Characteristics) of NATISPRAY)\n* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection, or guardianship or curatorship\n* Previous or current treatment with Belatacept\n* Severe high blood pressure (DBP ≥ 110 mm Hg and\u002For SBP ≥ 180 mm Hg)\n* Presence or history of functional or ligated or thrombosed bilateral arteriovenous fistula, preventing explorations\n* Pregnant, breastfeeding woman, or absence of proven effective contraception\n* Excessive alcohol consumption (no more than 10 drinks per week)\n* Active smoking with a daily consumption of more than 21 mg of nicotine per day or taking nicotine substitutes with a dose greater than 21 mg\u002F24 hours\n* Drug addiction or suspected illicit drug use\n* Patient participating or having participated in the 4 weeks preceding inclusion in a clinical trial","ALL","18 Years","75 Years",{"count":22,"type":23},44,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Kidney transplantation is the standard treatment for patients with end-stage renal failure.\n\nHowever, anticalcineurin inhibitors, the most widely used immunosuppressants, are involved in the occurrence of cardiovascular events, a major cause of premature death in these patients. They play an important role in the occurrence of endothelial dysfunction and increased arterial stiffness by decreasing the synthesis of nitric oxide (NO), promoting intrarenal arterial vasoconstriction and stimulating the production of pro-inflammatory cytokines. leading to the development of hypertension and chronic graft dysfunction.\n\nBelatacept, a more recently developed immunosuppressant and co-stimulation signal inhibitor, has shown an anti-rejection effect similar to cyclosporine with a better cardiovascular tolerance profile. Preliminary studies are contradictory on the influence of Belatacept on arterial stiffness. Furthermore, to date, no study has evaluated the impact of Belatacept on vasomotor endothelial function in humans, an indicator of NO bioavailability. The interest of this study is to demonstrate that patients taking Belatacept have an improvement in vascular function compared to patients taking anticalcineurins in order to consider an earlier change in immunosuppressive strategy in the event of vascular damage.",[29],"Kidney Diseases","RECRUITING","2026-06-05",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":34},"2026-04-30",{"date":38,"type":23},"2029-02-01",{"name":40,"class":41},"University Hospital, Rouen","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100538459","phase-2-safety-of-rotigotine-in-patients-with-autosomal-dominant-polycystic-kidney-disease-100538459","NCT06291116","Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease","ETERNAL-PKD","Inclusion Criteria:\n\n* ADPKD patients aged 18 to 60 years\n* Normotensive or hypertensive patients treated controlled (SBP\u002FDBP on daytime ABPM \\\u003C135\u002F85 mmHg less than 3 months old)\n* Patient having read and understood the information letter and signed the consent form\n* Effective contraception in women of childbearing age (for postmenopausal women, a confirmatory diagnosis should be obtained)\n* Patient benefiting from a social protection scheme\n\nExclusion Criteria:\n\n* Stage 4 or 5 renal insufficiency (GFR CKD-EPI \\\u003C30 ml\u002Fmin)\n* Renal transplant patients\n* Dialysis patients\n* History of myocardial infarction or stroke less than 6 months old\n* Severe hepatic insufficiency (Child-Pugh class C)\n* Patients currently being treated or treated in the 6 months preceding the trial with a dopamine agonist or antagonist\n* Systolic heart failure requiring hospitalization in the 6 months preceding inclusion or known heart failure with an LVEF \\\u003C30%\n* Orthostatic hypotension (decrease \\> 20 mm Hg)\n* Pregnant, breastfeeding woman, or proven absence of contraception\n* Excessive alcohol consumption (greater than 20 g\u002Fday)\n* History of addictive behavior, particularly gambling, compulsive purchasing or hypersexuality\n* Drug addiction or suspected illicit drug use\n* Taking other sedative medications or other central nervous system depressants (benzodiazepines, antipsychotics, antidepressants or neuroleptics with antiemetic intent)\n* Hypersensitivity to the active ingredient, rotigotine, or to one of its excipients\n* Known allergy to sulphites\n* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection, or guardianship or curatorship.","60 Years",{"count":52,"type":23},120,[54],"PHASE2","Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and is caused by mutations in the PKD1 or PKD2 genes, which encode polycystins 1 and 2. Patients develop renal cysts associated with a progressive decline in kidney function, ultimately leading to end-stage renal disease in approximately one third of cases. ADPKD is also characterized by early-onset hypertension and cardiovascular complications, notably intracranial aneurysms.\n\nThis phenotype is related to abnormal polycystin function in the primary cilia of renal epithelial and vascular endothelial cells, resulting in impaired mechanotransduction of shear stress induced by urinary and blood flow and subsequent alterations in multiple cellular functions. Experimental studies have suggested that stimulation of dopamine receptor type 5 (DR5) may restore endothelial mechanosensitivity. This hypothesis is supported by our preliminary results showing that local administration of dopamine improves endothelial function in patients with ADPKD through restoration of nitric oxide (NO) release in response to increased blood flow.\n\nConsistent with these findings, the IMPROVE-PKD study recently demonstrated similar beneficial effects on endothelial function and hemodynamics using rotigotine, a dopamine agonist administered via transdermal patches for two months at a low dose (4 mg\u002F24 h). Dopaminergic stimulation may also prevent renal abnormalities related to polycystin deficiency. We therefore hypothesize that rotigotine could slow the progression of ADPKD at both the renal and cardiovascular levels.\n\nThis phase 2 study aims to evaluate the long-term tolerability of rotigotine in patients with ADPKD and to collect preliminary data on its effects on renal outcomes.",[29],{"date":33,"type":34},{"date":59,"type":34},"2026-05-12",{"date":61,"type":23},"2030-07-01",{"name":40,"class":41},4,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":24,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100569393","collaborative-learning-to-achieve-refined-interventions-for-emory-kidney-disease-100569393","NCT06693661","Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease","Improving Access to Nephrology Treatment and Care Among Patients at Greatest Risk for Kidney Failure","CLARIFy-KD","Inclusion Criteria:\n\n* Identifies as African American or Black\n* Two estimated glomerular filtration rates (eGFRs) \\\u003C 29 separated by at least 90 days but within the past 2 years, or a Kidney Failure Risk Equation (KFRE) score of 10% or greater likelihood of kidney failure within the next 2 years\n* Had an encounter at Emory Healthcare through an ambulatory visit or inpatient stay (i.e., ER or hospital visit within the previous 2 months\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Currently on dialysis\n* currently receiving hospice care or other types of conservative management for terminal illness\n* Currently on waitlist, or referred for\u002For completed a transplant evaluation visit within the past 2 years\n* Kidney or another solid organ transplant\n* Active cancer treatment\n* Non-English speaking\n* Participating in another treatment or intervention study at the time of enrollment\n* Currently pregnant or planning to become pregnant at the time of recruitment",{"count":73,"type":23},600,[75],"NA","Through the use of community-engaged processes, this project seeks to develop and implement clinical decision support (CDS) and a kidney health coaching (KHC) intervention. The CDS seeks to streamline workflows to effectively screen, identify, and link to care for those patients with advanced chronic kidney disease (CKD).\n\nThe overall project goals are to 1.) Design and conduct community-engaged clinical trials to test new interventions that dismantle the systemic factors that contribute to kidney health disparities. 2.) Foster research collaborations between investigators, people living with kidney disease, community-based organizations, and other key stakeholders.\n\nResearchers aim to assess whether the KHC intervention is effective at delaying the transition to kidney replacement therapy (KRT) and central venous catheter use or death.",[29],[79,80,81,82],"African American","Health Disparities","Chronic Care Model (CCM)","Kidney Health Coach (KHC)","2026-06-03",{"date":85,"type":34},"2026-06-04",{"date":87,"type":34},"2026-03-10",{"date":89,"type":23},"2028-03",{"name":91,"class":41},"Emory University",2,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":24,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100413408","phase-2-a-study-of-the-safety-and-activity-of-sparsentan-for-the-treatment-of-patients-with-immunoglobulin-a-nephropathy-100413408","NCT04663204","A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy","A Multi-centre, Open-label, Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident (Cohort A) and Recurrent (Cohort B) Patients With Immunoglobulin A Nephropathy","SPARTAN","For Cohort A (Patients with Incident IgAN)\n\nInclusion Criteria:\n\n* The patient is willing and able to provide signed informed consent.\n* The patient can understand written and spoken English.\n* The patient is male or female, aged ≥18 years.\n* The patient has been diagnosed with biopsy-proven IgAN within the last 6 months (calculated from the date of kidney biopsy, upon which the IgAN-positive diagnosis was made, to the signing of the informed consent form).\n* The patient has a urine total protein value ≥0.5 g\u002Fday at screening.\n* The patient has an eGFR value ≥30 mL\u002Fmin\u002F1.73 m2 at screening.\n* The patient has not previously been treated with ACEI and\u002For ARB therapy for IgAN OR has not received ACEI and\u002For ARB therapy within the last 12 months.\n* The patient has a systolic BP ≤150 mmHg and ≥100 mmHg, and diastolic blood pressure ≤100 mmHg and ≥60 mmHg at screening.\n* Women of childbearing potential (WOCBP), beginning at menarche, must agree to the use of one highly reliable (ie, can achieve a failure rate of \\\u003C1% per year) method of contraception from 7 days prior to the first dose of trial medication until 90 days after the last dose of trial medication. Highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with inhibition of ovulation, or an intrauterine device (IUD) in place for at least 3 months. One additional barrier method must also be used during sexual activity, such as a diaphragm or diaphragm with spermicide (preferred), or male partner's use of male condom or male condom with spermicide), from Day 1 until 90 days after the last dose of trial medication.\n\nWOCBP are defined as those who are fertile, following menarche and until becoming postmenopausal unless permanently sterile; permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as amenorrhoea for more than 24 consecutive months without an alternative medical cause; women on hormone replacement therapy must have a documented plasma follicle-stimulating hormone level ≥40 mIU\u002FmL. All WOCBP must have a negative pregnancy test at Visit 1 (serum test) and Visit 2 (urine, with positive results confirmed by serum).\n\nExclusion Criteria:\n\n* The patient has IgAN secondary to another condition (eg, systemic lupus erythematosus, liver cirrhosis).\n* The patient, in the opinion of the Investigator, has a rapidly progressive glomerulonephritis (rapid decline in GFR and crescents on biopsy).\n* The patient has a history of type 1 diabetes mellitus, uncontrolled type 2 diabetes mellitus (haemoglobin A1c \\[HbA1c\\] \\>8%), or nonfasting blood glucose \\>10 mmol\u002FL (180 mg\u002FdL) at screening.\n* The patient has undergone any organ transplantation, with the exception of corneal transplants.\n* The patient requires any of the prohibited concomitant medications (see Section 14.4).\n* The patient has been taking any systemic immunosuppressive medications for \\>2 weeks within 6 months prior to screening.\n* The patient has a documented history of heart failure (New York Heart Association Class II-IV) and\u002For previous hospitalisation for heart failure or unexplained dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea, ascites, and\u002For peripheral oedema.\n* The patient has clinically significant cerebrovascular disease (transient ischemic attack or stroke) and\u002For coronary artery disease (hospitalisation for myocardial infarction or unstable angina, new onset of angina with positive functional tests, coronary angiogram revealing stenosis, or a coronary revascularisation procedure) within 6 months prior to screening.\n* The patient has jaundice, hepatitis, or known hepatobiliary disease (including asymptomatic cholelithiasis), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2 times the upper limit of the normal range at screening.\n* The patient has a history of malignancy other than adequately treated basal cell or squamous cell skin cancer or cervical carcinoma within the past 2 years.\n* The patient has a screening haematocrit value \\\u003C27% or haemoglobin value \\\u003C90 g\u002FL (9 g\u002FdL).\n* The patient has a screening potassium value of \\>5.5 mmol\u002FL (5.5 mEq\u002FL).\n* The patient has a history of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).\n* The patient has a history of serious side effects or allergic response to any AngII or ERA, including sparsentan, or has a hypersensitivity to any of the excipients in the IMP.\n* The female patient is pregnant, plans to become pregnant during the course of the trial, or is breastfeeding.\n* The patient has participated in a trial of any investigational product within 28 days prior to screening, or plans to participate in such a trial during the course of this trial.\n* The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the trial, including the ability to swallow the IMP whole.\n* The patient, in the opinion of the Investigator, has a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity.\n* Patients with a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity will be reviewed before consideration of the patient for enrolment.\n\nFor Cohort B (Recurrent IgAN following kidney transplantation)\n\nInclusion Criteria:\n\n* Male and female aged ≥18 years\n* Diagnosis of recurrent IgAN based on histological analysis of a transplanted kidney biopsied within the last 6 months\n* A time period of \\>12 months since kidney transplantation\n* UPCR ≥50 mg\u002Fmmol (≥0.44 g\u002Fg) and eGFR value ≥25 mL\u002Fmin\u002F1.73 m2\n* For patients on an ACEI and\u002For ARB, and\u002For SGLT2 inhibitor, the dosing regimen is stable for at least 6 weeks prior to and during the screening period\n* Tacrolimus treatment as part of standard of care immunosuppression following kidney transplantation\n* Systolic BP ≤150 mmHg and ≥100 mmHg, and diastolic blood pressure ≤100 mmHg and ≥60 mmHg at screening.\n* Female patients not of childbearing potential, or of childbearing potential and agreeing to use the contraceptive methods listed in Section 5.1\n\nExclusion Criteria:\n\n* The patient has recurrent IgAN secondary to another condition or cause (eg, systemic lupus erythematosus, liver cirrhosis).\n* Evidence of alternative pathology on the kidney transplant biopsy as the main cause for proteinuria (e.g. diabetic nephropathy, chronic transplant glomerulopathy, mTORi treatment)\n* Patient has multiorgan transplants (with the exception of corneal transplants)\n* Immunosuppressive therapy (IST) regimen for kidney transplant or other chronic immunosuppressive therapies that is not stable for \\>6 weeks prior to Day 1. Exceptions include routine protocol tapering and for tacrolimus, changes in dose to meet target level\n* Treatment with enteric budesonide (nefecon) within 6 months prior to screening, or planned use of enteric budesonide (nefecon) at any time during the study.\n* Current treatment for surgical complications\n* \\\u003C3 months after anti-rejection treatment or active rejection\n* Active bacterial, fungal or viral infection and\u002For active treatment of infection including BKV, CMV, HIV, Hepatitis B and C \\\u003C3 months prior to and during the screening period\n* Current treatment for surgical complications\n* Uncontrolled diabetes mellitus (defined by HbA1C \\>8% (\\>64 mmol\u002Fmol)\n* History of heart failure (New York Heart Association (NYHA) Class II-IV)\n* Jaundice, hepatitis, or known hepatobiliary disease\n* Malignancy within the past 2 years with the exception of adequately treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin, with no evidence or recurrence\n* Haematocrit \\\u003C27%, haemoglobin \\\u003C90 g\u002FL (9 g\u002FdL), or potassium \\>5.5 mmol\u002FL (5.5 mEq\u002FL)\n* History of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition)\n* History of serious side effects or allergic response to any angiotensin II antagonist or endothelin receptor antagonist (ERA) or dual endothelin and angiotensin receptor antagonist (DEARA e.g. sparsentan)\n* The female patient is pregnant, plans to become pregnant during the course of the study, or is breastfeeding.\n* The patient has participated in a study of any investigational product within 28 days prior to screening, or plans to participate in such a study during the course of this study.\n* The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study, including the ability to swallow the IMP whole.\n* The patient, in the opinion of the Investigator, has a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity.",{"count":102,"type":23},24,[54],"To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and in (2: Cohort B) patients with recurrent IgAN following kidney transplantation.",[106,29,107,108,109,110],"Immunoglobulin A Nephropathy","Glomerulonephritis, IGA","Glomerulonephritis","Autoimmune Diseases","Immune System Diseases","2026-05-29",{"date":83,"type":34},{"date":114,"type":34},"2020-12-10",{"date":116,"type":23},"2027-12-31",{"name":118,"class":41},"University of Leicester",6,{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":132,"conditions":133,"keywords":139,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":161},"100582054","phase-3-open-label-extension-study-of-zigakibart-in-adults-with-iga-nephropathy-100582054","NCT06858319","Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.","A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.","Inclusion Criteria:\n\n1. Signed informed consent must be obtained prior to participation in the OLE study.\n2. Completion of the parent study (both participants assigned to receive the investigational product and placebo) as defined by the respective protocol.\n3. Per Investigator's clinical judgment, the participant may benefit from receiving open-label treatment of zigakibart 600 mg s.c. Q2W.\n\nExclusion Criteria:\n\n1. Participants who prematurely withdrew from zigakibart parent studies in IgAN for any reason.\n2. Participants who at the time of first study treatment administration in the OLE are receiving chronic dialysis (≥30 days) or who require kidney transplantation.\n3. Acute kidney injury (AKI), defined by AKIN criteria (Mehta et al 2007) within 4 weeks of first study treatment administration in the OLE study.\n4. Clinical suspicion or diagnosis of rapidly progressive glomerulonephritis (RPGN), defined by KDIGO guidelines, or another glomerulopathy at the time of first study treatment administration in the OLE study.\n5. Received a live vaccination within 12 weeks prior to first study treatment administration in the OLE study or plan to have a live vaccination within 6 months after the last dose of study treatment.\n6. Use of systemic corticosteroid therapy (including budesonide) or other immunosuppressive therapy such as but not limited to mycophenolate, azathioprine, cyclosporine, tacrolimus, cyclophosphamide, etc., and herbs such as Tripterygium Wilfordii Hook F, Caulis sinomenii, and Sinomenium acutum for \\> 2 weeks in the 12 weeks prior to first study treatment administration in the OLE study; use of rituximab within 180-days of first study treatment administration in the OLE study.\n7. Current severe infection at the time of first study treatment in the OLE study or history of recurrent, severe, infections as determined by the Investigator.\n8. Newly diagnosed positive serology for hepatitis A virus IgM antibodies (anti-HAV IgM), hepatitis B surface antigen (HBsAg), detectable hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) antibodies (participants who completed treatment and are persistently antibody positive but have documentation of negative HCV polymerase chain reaction \\[PCR\\] will be allowed), or antibodies to HIV-1 and\u002For HIV-2.\n9. Newly diagnosed malignancy (participants with basal cell carcinoma that was completely resected or curatively treated cervical carcinoma in situ or low-risk prostate cancer (i.e., Gleason score \\\u003C 7 and prostate specific antigen \\\u003C 10 ng\u002FmL) are eligible for the study).\n10. Pregnancy or breastfeeding or intent to become pregnant or to donate sperm during the study period and until 24 weeks after last dose.\n11. History or evidence of any other clinically significant medical or psychiatric disorder, condition, disease, or laboratory finding that, in the discretion of the Investigator, constitutes an uncertain or unfavorable benefit-risk for continued long-term therapy with zigakibart.\n12. Confirmed IgG levels \\\u003C 3 g\u002FL prior to first study treatment administration in the OLE study.\n13. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, from menarche until becoming post-menopausal unless they are using highly effective methods of contraception (failure rate \\\u003C 1% per year) while taking study treatment and for 24 weeks after stopping study treatment. Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., hormonal profile confirming menopause and\u002For age-appropriate history of vasomotor symptoms).\n14. Sexually active males unwilling to use a highly effective methods of contraception during intercourse while taking study treatment and for 24 weeks after stopping study treatment. In addition, male participants must not donate sperm for the time period specified above.\n\nHighly effective contraception methods for both women and men include:\n\n* Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Note that periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n* Bilateral oophorectomy with or without hysterectomy, total hysterectomy or bilateral salpingectomy at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment are they considered to be not of childbearing potential.\n* Bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking study treatment).\n* Sterilization (vasectomy) of male partner(s) of the female participant at least 6 months prior to first study treatment provided partner(s) has(have) received medical confirmation of surgical success.\n* Use of hormonal contraception methods:\n* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, intravaginal or transdermal.\n* Progestogen-only hormonal contraception (where inhibition of ovulation is not the primary or only mode of action): oral, injectable or implantable.\n* Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS). In case of use of hormonal contraception, women should have been stable on the same method for a minimum of 3 months before taking study treatment.","100 Years",{"count":129,"type":23},220,[131],"PHASE3","The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.",[29,134,135,108,136,107,137,138],"Kidney Diseases, Chronic","Urological Diseases","Glomerular Disease","Glomerulopathy","Immunoglobulin Disease",[140,141,142,143,144,108,145,109,110,29,107,146,147,148,149,150],"Urologic Diseases","Female Urogenital Diseases","Female Urogenital Diseases and Pregnancy Complications","Urogenital Diseases","Male Urogenital Diseases","Nephritis","Primary IgA \u002F Immunoglobulin A nephropathy","eGFR","UPCR","UACR","FUB523","2026-05-28",{"date":153,"type":34},"2026-06-01",{"date":155,"type":34},"2025-07-28",{"date":157,"type":23},"2031-06-25",{"name":159,"class":160},"Novartis Pharmaceuticals","INDUSTRY",18,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":42},"100607913","supporting-veterans-with-kidney-disease-through-food-as-medicine-100607913","NCT07194733","Supporting VETerans With Kidney Disease Through Food As Medicine","Supporting VETerans With Kidney Disease Through Food As Medicine: the Community-based VET FAM Study","VETFAM","Inclusion Criteria:\n\n* Age 18+\n* CKD stage 3b or 4\n* Positive screen for nutrition insecurity (e.g., Tufts screener)\n* Receiving care at the VA and residing in Food Bank of the Rockies service area\n* Ability to provide informed consent, English\n\nExclusion Criteria:\n\n* Stage 1-3a CKD and stage 5 CKD\u002FESRD (dialysis or transplant)\n* Currently enrolled in a conflicting dietary trial\n* Unwilling or unable to provide informed consent",{"count":171,"type":23},20,[75],"The goal of this pilot clinical trial is primarily learn if produce boxes improve clinical outcomes among Veterans with kidney disease and food or nutrition insecurity. Secondly, the study will capture Veterans qualitative perspectives, experience, and engagement through semi-structured interviews.",[29,175,176,177],"Food\u002FNutrition Insecurity","Diabetes","Hypertension",{"date":179,"type":34},"2026-05-04",{"date":181,"type":34},"2025-01-01",{"date":183,"type":23},"2027-03",{"name":185,"class":186},"VA Eastern Colorado Health Care System","FED",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":194,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100586216","proteomic-analysis-of-amniotic-fluid-to-predict-postnatal-renal-function-in-fetuses-with-renal-and-urinary-tract-malformations-100586216","NCT06912490","Proteomic Analysis of Amniotic Fluid to Predict Postnatal Renal Function in Fetuses With Renal and Urinary Tract Malformations","PAPER FACE","Inclusion Criteria:\n\n* All fetuses with bilateral renal development anomalies with structural changes in the parenchyma, with or without associated urinary tract anomalies;\n* Signed informed consent of the mother\n* Non-opposition of the father.\n\nExclusion Criteria:\n\n* Unilateral abnormality of renal development\n* Any pregnancy for which amniocentesis may represent a risk for the fetus or the mother\n* Twin pregnancies\n* Pregnant woman protected by law (guardianship, curatorship)","FEMALE",{"count":196,"type":23},78,[75],"The aim of this project is to validate a previously established amniotic fluid 98 peptide signature predictive of post-natal outcome in fetuses with congenital anomalies of the kidney and the urinary tract (CAKUT) in a \"real\" clinical context. It includes the feasibility of collecting, transporting and analyzing the amniotic fluid peptidome from clinical centers all over France and of providing the result in a clinically accepted time-frame. Therefore, this multicenter study will not only allow to determine the added value of such new prenatal test but also to ensure the feasibility of its introduction in the management of CAKUT pregnancies.",[29],[201,202,203,204,205,206],"Antenatal","fetal bilateral nephropathies","renal function","prognosis","proteomic analysis","renal ultrasound","2026-04-28",{"date":179,"type":34},{"date":210,"type":34},"2025-07-18",{"date":212,"type":23},"2029-12-20",{"name":214,"class":41},"University Hospital, Toulouse",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":223,"targetDuration":4,"studyType":24,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":92},"100578386","phase-2-navigate-kidney-a-multi-level-intervention-to-reduce-kidney-health-disparities-100578386","NCT06810622","NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities","Navigate Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities Among Individuals With Kidney Disease","NAV-Kidney","Inclusion Criteria:\n\n* Adults ≥ 18 years of age,\n* Adults who are not pregnant,\n* Adults who are not incarcerated,\n* Adults who have advanced kidney disease with an eGFR of 15-29 mL\u002Fmin\u002F1.73m2). No other measures are used to identify eligible patients.\n\nExclusion Criteria:\n\n* Previous kidney transplant\n* Previous surgery for dialysis such as an arteriovenous fistula, arteriovenous graft, or peritoneal dialysis catheter placement\n* On chronic dialysis\n* Conservative management or primary goal is palliation\n* Incarcerated\n* Pregnant\\*\n* Under 18 years of age\n* Moderate to severe dementia\n* Deaf persons\n* Lacking health insurance\\*\\*\n* Investigator Discretion: Individuals who, in the judgment of the Site PI (or designee), are deemed unsuitable for participation due to behavioral or logistical circumstances that could compromise study integrity or the safety of the participant or staff.",{"count":224,"type":23},448,[54],"The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for individuals with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for individuals with advanced CKD. The project will have four (4) aims.",[29,228],"Chronic Kidney Diseases",[230,231,232,233],"Kidney","Chronic","Dialysis","Transplant","2026-04-27",{"date":236,"type":34},"2026-05-01",{"date":238,"type":34},"2026-03-18",{"date":240,"type":23},"2029-05-15",{"name":242,"class":41},"University of Colorado, Denver",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":251,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":265,"leadSponsor":267,"locationsCount":42},"100609665","rutgers-university-study-of-the-genetics-of-kidney-disease-100609665","NCT07217535","Rutgers University Study of the Genetics of Kidney Disease","The Rutgers University Study of the Genetics of Kidney Disease","rugcc-kd","Inclusion Criteria:\n\n* age 18 years or older\n* currently living in the United States\n* able to understand and follow written instructions in English\n* have access to the internet and a computer, laptop, tablet or smart phone\n* willing to provide written informed consent for participation\n* willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home\n* willing to complete a survey with questions about health related to the study of kidney disease\n\nExclusion Criteria:\n\n* Not able to meet or fulfill any of the inclusion criter",true,{"count":253,"type":23},50000,"OBSERVATIONAL","The goal of this observational study is to learn more about how genes impact the risk of kidney disease. Anyone 18 or older living in the US is eligible, and a diagnosis of kidney disease is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and request a saliva collection kit sent through US mail. In return, study participants may opt to receive information about their genetic ancestry at no cost.",[257,258,259,29,134,260],"Kidney Disease","Kidney Disease, Chronic","Kidney Disease, End-Stage","Kidney Diseases,Cystic","2026-04-23",{"date":263,"type":34},"2026-04-24",{"date":261,"type":34},{"date":266,"type":23},"2028-10-31",{"name":268,"class":41},"Rutgers, The State University of New Jersey",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":277,"maxAge":278,"enrollmentInfo":279,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":42},"100626454","effect-of-comprehensive-spa-care-on-kidney-and-urological-conditions-a-clinical-study-in-adult-patients-100626454","NCT07435844","Effect of Comprehensive Spa Care on Kidney and Urological Conditions: A Clinical Study in Adult Patients","Objective Assessment of the Effect of Comprehensive Spa Care on Patients With Chronic Kidney and Urological Diseases: A Prospective Interventional Clinical Study","Uro-Nefro","Inclusion Criteria:\n\n* Male or female aged 40 to 70 years\n* Prescribed comprehensive spa care (KLP) for one of the following indications: recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract resistant to antibiotic and pharmacological treatment, with at least 12 months of continuous urological care (indication VIII\u002F1); cystic kidney disease (indication VIII\u002F1); nephrolithiasis without urinary tract obstruction or nephrocalcinosis (indication VIII\u002F2); conditions after kidney or urinary tract surgery, including endovesical procedures, complicated prostatectomy, nephrolithotripsy, or recovery after extracorporeal shock wave lithotripsy (indication VIII\u002F3); chronic prostatitis or chronic prostatovesiculitis resistant to pharmacological and antibiotic treatment, with at least 12 months of continuous urological care (indication VIII\u002F4)\n* Able to walk from the sanatorium to the colonnade and back three times daily\n* Willing to follow the treatment plan\n* Signed informed consent\n\nExclusion Criteria:\n\n* Contraindications according to Czech Decree No. 2\u002F2015 Coll. on spa treatment criteria (pregnancy, acute illness, etc.)\n* Significant mobility limitation or severe neuropathy preventing daily walks to the colonnade\n* Significant obesity or inability to briefly hold breath (required for ultrasound examination)\n* Alcohol intake exceeding 20 g of ethanol per day\n* Nephrolithiasis with urinary tract obstruction\n* History of esophageal or gastric variceal bleeding\n* Severe comorbidities that could affect treatment outcomes\n* Active oncological disease\n* Unwillingness to adhere to the treatment plan","40 Years","70 Years",{"count":280,"type":23},150,[75],"This is a single-arm, pretest-posttest study evaluating the effects of a 21-day comprehensive spa care (Komplexní lázeňská léčebně rehabilitační péče, KLP) on patients with nephrological and urological conditions treated at a spa facility in Mariánské Lázně, Czech Republic.\n\nThe study enrolls 150 adult patients (75 men and 75 women), aged 40-70 years, who are prescribed KLP for indications VIII\u002F1 (recurrent and chronic non-tuberculous inflammation of the kidneys and urinary tract), VIII\u002F2 (nephrolithiasis without urinary tract obstruction, nephrocalcinosis), VIII\u002F3 (conditions after kidney and urinary tract surgery), and VIII\u002F4 (chronic prostatitis or prostatovesiculitis resistant to pharmacological treatment).\n\nThe spa treatment consists of the use of natural healing resources of Mariánské Lázně, including a mineral spring drinking cure, balneotherapy (mineral water baths), peloid therapy, carbon dioxide therapy, climatotherapy, exercise therapy, and dietotherapy. The standard treatment duration is 21 days, during which each patient receives a total of 63 therapeutic procedures and drinks mineral spring water three times daily.\n\nPatients undergo assessments at the beginning (days 1-3) and at the end (days 19-21) of their treatment. Assessments include physical examination, abdominal and urinary tract ultrasound, blood and urine sampling with laboratory analysis, body composition measurement using bioelectrical impedance analysis (InBody), and psychometric questionnaire surveys.\n\nThe primary aim of the study is to objectively assess the therapeutic effect of comprehensive spa care on nephrological and urological diseases by comparing pre-treatment and post-treatment clinical, laboratory, and patient-reported outcomes.\n\nThe study was approved by the Ethics Committee of the University Hospital and Faculty of Medicine in Pilsen (decision of November 2, 2023, ref. no. 437\u002F23).",[140,284,285,286,287,29],"Urinary Tract Infections","Nephrolithiasis","Nephrocalcinosis","Prostatism",[289,290,291,292,293,294,295],"Balneotherapy","Spa Treatment","Mineral Water Drinking Cure","Mariánské Lázně","Nephrology","Urology","comprehensive spa care","2026-04-21",{"date":263,"type":34},{"date":299,"type":34},"2026-04-07",{"date":301,"type":23},"2027-04-30",{"name":303,"class":41},"Institute of Spa and Balneology, public research institution",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":18,"minAge":311,"maxAge":19,"enrollmentInfo":312,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":316,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":4},"100634735","pediatric-renal-emergencies-presentations-and-outcomes-at-sohag-university-hospitals-100634735","NCT07543549","Pediatric Renal Emergencies: Presentations and Outcomes at Sohag University Hospitals","Variable Manifestations and Outcomes of Renal Diseases Among Children Presenting to the Emergency Room at Sohag University Hospitals","Inclusion Criteria:\n\n* Children aged 1 month to 18 years. Presentation to the emergency room at Sohag University Hospitals with signs and\u002For symptoms suggestive of renal involvement (e.g., edema, hematuria, oliguria\u002Fanuria, flank pain, hypertension).\n\nPatients with a known history of renal disease presenting with acute exacerbation.\n\nWritten informed consent obtained from parents or legal guardians.\n\nExclusion Criteria:\n\n* Incomplete or missing essential clinical, laboratory, or imaging data. Refusal or inability to obtain written informed consent from parents or legal guardians.\n\nPatients with suspected renal symptoms later confirmed to have non-renal causes.\n\nPatients who received renal replacement therapy prior to presentation at another facility.","1 Month",{"count":313,"type":23},50,"Renal diseases in children present with a wide spectrum of clinical manifestations, ranging from mild urinary abnormalities to severe acute kidney injury requiring urgent management. Early recognition in the emergency setting is essential to improve outcomes, yet data on pediatric renal emergencies in Upper Egypt remain limited.\n\nThis prospective cohort study aims to characterize the clinical presentations of renal diseases among children presenting to the emergency room at Sohag University Hospitals, determine the prevalence of specific renal conditions, and evaluate immediate management outcomes and short-term follow-up after discharge.",[29],"NOT_YET_RECRUITING","2026-04-15",{"date":319,"type":34},"2026-04-22",{"date":31,"type":23},{"date":322,"type":23},"2027-10-05",{"name":324,"class":41},"Sohag University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":42},"100494556","phase-1-effect-of-dapagliflozin-on-metabolomics-and-cardiac-mechanics-in-chronic-kidney-disease-100494556","NCT05719714","Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease","Inclusion Criteria:\n\n1. \\>18 years of age\n2. eGFR 25-60 ml\u002Fmin\u002F1,73m2 (eGFR = estimated glomerular filtration rate)\n3. On stable doses of diuretics and\u002For angiotensin converting enzyme inhibitor or angiotensin receptor blocker\n4. Evidence of subclinical heart failure with preserved ejection fraction at their pre-exercise echocardiogram (defined as meeting 3\u002F5 of the American Society of Echocardiography (ASE) criteria for diastolic dysfunction \\[septal e'\\\u003C7 cm\u002Fwc, average E\u002Fe' ratio\\>14, left atrial volume index \\>34 mL\u002Fm2, and peak TR velocity \\>2.8 m\u002Fsec\\] or absolute left ventricular longitudinal strain \\\u003C 18%, left atrial reservoir strain (LARS) \\\u003C 25% on 2d speckle tracking echocardiography), lack of augmentation of LVLS or LARS during exercise, or peak VO2 Females: ≤ 18 mL\u002Fkg\u002Fmin, peak VO2 Males: ≤ 20 mL\u002Fkg\u002Fmin on cardiopulmonary exercise testing.\n\nExclusion Criteria:\n\n1. presence or history of diabetes\n2. coronary revascularization within the last 6 months\n3. hemodynamically significant valvular disease\n4. significant lung disease requiring home oxygen\n5. angina (chest pain)\n6. non-revascularized myocardial ischemia\n7. systolic BP \\\u003C100 or \\>180 mmHg\n8. pregnancy\n9. clinical heart failure symptoms\n10. history of systemic disease processes that can cause HFpEF such as amyloidosis or sarcoidosis\n11. any musculoskeletal or chronic condition that will interfere with completion of cardiac testing\n12. active cancer\n13. immunosuppressive therapy\n14. baseline or pre-exercise echocardiogram demonstrates a reduced ejection fraction \\\u003C 50%\n15. currently on sodium glucose cotransporter 2 inhibitor (SGLT2i) therapy\n16. Hypersensitivity to a SGLT2i\n17. Pre-existing liver disease\n18. ALT\u002FAST\\> 3x normal (ALT = alanine aminotransferase AST = aspartate aminotransferase)\n19. history of recurrent urinary tract infections (in the opinion of the investigator) or a urinary tract infection in the last 3 months","85 Years",{"count":333,"type":23},60,[335,54],"PHASE1","The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.",[228,338,29,339],"Heart Failure With Preserved Ejection Fraction","Heart Failure",[341,342,343],"kidney","heart failure","kidney diseases","2026-04-06",{"date":346,"type":34},"2026-04-13",{"date":348,"type":34},"2024-01-16",{"date":350,"type":23},"2026-09-30",{"name":352,"class":41},"Northwestern University",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":361,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":42},"100631478","methods-for-nutrition-inflammation-kidney-function-aging-body-composition-and-hydration-among-older-patients-100631478","NCT07501195","Methods for Nutrition, Inflammation, Kidney Function, Aging, Body Composition, and Hydration Among Older Patients","Methods for Assessing Nutrition, Inflammation, Kidney Function, Aging, Body Composition, and Hydration Among Older Patients - An Observational Study (MIKADO)","MIKADO","Inclusion Criteria:\n\n* 65 years or older (group 1, 4 and 5)\n* 90 years or older (group 3)\n* Acute admission (group 1, 2)\n* Cognitively able to cooperate (group 1)\n* Able to read and speak Danish (group 1, 2, 3, 4, 5, 6)\n* BMI ≥ 35 kg\u002Fm2 (group 4)\n* Prednisolon treatment for COPD (≥ 37,5 mg daily) (group 5)\n* Amputation(s) of crus or femur (non-traumatic) (group 6)\n\nExclusion Criteria:\n\n* Isolation (group 1, 2, 3, 4, 5, 6)\n* Terminal treatment (group 1, 2, 3, 4, 5, 6)\n* Suicidal (group 1, 2, 3, 4, 5, 6)\n* Active Immune suppressing treatment (group 2, 3, 4, 5, 6)\n* Oedemas (group 2, 3, 4, 5, 6)\n* In active treatment for cancer (group 2, 3, 4, 5, 6)","65 Years",{"count":363,"type":23},500,"The goal of this observational study, is to improve the diagnostic assessment method of malnutrition and kidney diseases, amongst hospitalized and low priority patients, by evaluating modern methodology and biomarkers, with regards to an estimate of the nutritional status and kidney diseases, against current gold standards, and also investigate how body composition, hydration, inflammation and age affect the assessments.",[366,29,367],"Malnutrition Elderly","Dehydration","2026-03-26",{"date":370,"type":34},"2026-03-30",{"date":372,"type":34},"2026-03-01",{"date":374,"type":23},"2035-09",{"name":376,"class":41},"Ove Andersen",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":24,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":400},"100577485","phase-3-kidney-transplant-preemptive-therapy-or-prophylaxis-for-cmv-prevention-in-dr-recipients-100577485","NCT06798909","Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients","Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients","KPoP","Inclusion Criteria:\n\n1. Subject or legally authorized representative has provided written informed consent.\n2. Age ≥ 18 years of age at the time of informed consent.\n3. Negative for IgG antibody to CMV as assessed in a CLIA-certified laboratory between 28 days prior to transplant and up to 7 days post-transplant but prior to randomization.\n4. Received a kidney transplant from a CMV seropositive (IgG positive) donor in the past 7 days prior to enrollment\n5. Individuals of reproductive (childbearing) potential must have a negative pregnancy test (serum or urine) collected prior to randomization (SOC results within 7 days prior to transplant may be used), and must also agree to use a medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence from the time of enrollment through until discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.\n\n   NOTE: Individuals of reproductive potential are defined as individuals who have reached menarche and who have not been post-menopausal for at least 12 consecutive months with follicle stimulating hormone (FSH) ≥40 IU\u002FmL or 24 consecutive months if an FSH is not available, i.e., who have had menses within the preceding 24 months, and have not undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, or salpingectomy).\n6. If male, must agree to practice a barrier method of contraception or abstinence from the time of enrollment through 3 months after discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.\n\nExclusion Criteria:\n\n1. In the opinion of the investigator, participants who are unable or unwilling to undergo preemptive therapy protocol (weekly CMV PCR, etc.)\n2. Patients who are breastfeeding or planning to breastfeed within 6 months post-transplant\n3. Allergy to valganciclovir\u002Fganciclovir or Letermovir\n4. Receipt of immunoglobulin or CMV-specific immunoglobulin within the last 3 months (this includes COVID convalescent plasma)\n5. Currently enrolled or anticipated enrollment in another interventional study that, in the opinion of scientific leadership team, could affect evaluation of the primary safety and\u002For efficacy outcomes.\n6. Most recent platelet count post-transplant \\\u003C25,000\u002FuL\n7. Most recent ANC performed post-transplant \\\u003C1000\u002FuL\n8. Multi-organ transplant (except simultaneous kidney-pancreas) within the past 7 days\n9. Prior or planned receipt of a hematopoietic cell transplant\n10. Baseline immunodeficiency prior to transplant, including but not limited to:\n\n    1. Known or suspected HIV infection\n    2. Congenital or acquired immunodeficiency\n11. Unacceptable immunosuppression\n\n    1. Receipt of desensitization therapy prior to kidney transplant, or\n    2. Receipt of an ABO-incompatible kidney transplant except A2 to blood type B",{"count":386,"type":23},360,[131],"This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \\[both dose adjusted per Food and Drug Administration (FDA) label\\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study.\n\nEstimated Time to Complete Enrollment: 4 years",[390,391,29],"Cytomegalovirus (CMV)","Kidney Transplant; Complications",{"date":393,"type":34},"2026-04-01",{"date":395,"type":34},"2025-07-22",{"date":397,"type":23},"2031-05-31",{"name":399,"class":41},"University of California, San Francisco",5,{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":251,"sex":18,"minAge":4,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":24,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":92},"100517537","urine-and-ultrasound-screening-for-kidney-disease-in-children-100517537","NCT06018831","Urine and Ultrasound Screening for Kidney Disease in Children","Inclusion Criteria:\n\n* All consecutive live newborn infants(regardless of physical condition)\n* Complete at least 3 years of follow-up\n\nExclusion Criteria:\n\n* Declining the screening\n* Missing","6 Years",{"count":409,"type":23},13000,[75],"The aim of this study is to early detect kidney disease in the natural population cohort of children by urine and ultrasound screening, to assist in the precise prevention and treatment of children's kidney disease, and to establish a risk prediction system for children's kidney disease. About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Through the project, child who is found with abnormal urine or ultrasound result will be referred to Children's Hospital of Fudan University to get further examination and treatment.",[29,413,414,415,416],"Diagnostic Techniques","Ultrasound","Urinalysis","Child, Only","2026-03-24",{"date":419,"type":34},"2026-03-27",{"date":421,"type":34},"2022-04-12",{"date":423,"type":23},"2028-02",{"name":425,"class":41},"Children's Hospital of Fudan University",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":455},"100566577","phase-3-a-contrast-medium-sparing-strategy-using-automated-co2-injection-during-pvi-for-prevention-of-major-adverse-kidney-events-make-100566577","NCT06656988","A Contrast Medium Sparing Strategy Using Automated CO2 Injection During PVI for Prevention of Major Adverse Kidney Events (MAKE)","A Contrast Medium Sparing Strategy Using Automated Carbon Dioxide Injection During PERIpheral Vascular Interventions for PREVENTion of Major Adverse Kidney Events (MAKE): the PeriPREVENT Randomized Controlled Trial","PeriPREVENT","Inclusion Criteria:\n\n1. Symptomatic peripheral arterial disease presenting with either acute symptoms (Rutherford clinical categories I-IIb) or chronic symptoms (Fontaine stages IIb-IV or Rutherford clinical categories 2-6)\n2. Planned peripheral vascular intervention of infrainguinal arteries due to femoropopliteal and\u002For infrapopliteal lesions\n3. Increased risk of CA-AKI identified by a baseline risk score of ≥ 5 points based on a published dedicated PVI risk score and a pre-angiographic estimated glomerular filtration rate (eGFR) \\< 60 ml\u002Fmin\u002F1.73 m²\n4. Both angiographic strategies seem feasible at the investigator's discretion\n5. Age 18 years or older\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Very agitated patients\n2. Patients with planned full anaesthesia during procedure\n3. Patients with a life-expectancy less than one year\n4. Patients confined to bed that are completely non-ambulatory\n5. Known acute renal failure or known unstable renal function as evidenced by a recent increase in serum creatinine (SCr) of \\> 0.5 mg\u002Fdl or \\> 25% within 7 days\n6. Iodinated contrast medium exposure within 7 days prior to procedure with change in SCr ≥ 0.1 mg\u002Fdl on two SCr measures ≥ 24 h apart\n7. Advanced chronic kidney disease (CKD) with an eGFR \\< 30 ml\u002Fmin\u002F1.73m² and\u002For dialysis\n8. Current use of nephrotoxic agents (aminoglycoside antibiotics, sulfonamides, amphotericin B, or pentamidine), or an active chemotherapy agent\n9. Acute or chronic pulmonary disease requiring oxygen therapy\n10. Patients with known patent foramen ovale or atrial septal defect\n11. Patients with planned nitrous oxide anaesthesia during intervention\n12. Patients with manifest hyperthyroidism or manifest thyrotoxicosis\n13. Known allergies or hypersensitivity to iodinated contrast media that cannot be adequately pre-treated prior to index procedure\n14. Patients with decompensated heart failure\n15. Patients with manifest tetany\n16. Planned further procedure with a need for \\> 10 ml of iodinated contrast medium (CM) in any location (e.g., CT scan, coronary angiography) within a period of 90 days\n17. Any surgical procedure (except minor amputations) or intervention performed within 30 days prior to or planned within 90 days post index procedure\n18. Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) until day 30 after PVI.\n19. Participation in other interventional trials. Exceptions are described in the trial protocol.\n20. Suspected lack of compliance\n21. Pregnant or nursing women",{"count":435,"type":23},1960,[131],"The primary objective of the trial is to evaluate if an iodinated contrast medium sparing strategy using automated Carbon Dioxide (CO2) Injection prevents Major Adverse Kidney Events up to 90 days (MAKE90) in patients at moderately elevated risk for contrast-associated acute kidney injury (CA-AKI) undergoing infrainguinal peripheral vascular interventions (PVI).",[439,29],"Peripheral Vascular Diseases",[441,442,443,444,445,446],"carbon dioxide","contrast medium","iodinated contrast medium","CA-AKI","angiography","angioplasty",{"date":448,"type":34},"2026-03-23",{"date":450,"type":34},"2025-04-14",{"date":452,"type":23},"2029-02",{"name":454,"class":41},"University of Leipzig",11,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":251,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":462,"targetDuration":464,"studyType":254,"phases":4,"briefSummary":465,"conditions":466,"keywords":472,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":42},"100416731","archival-of-human-biological-samples-in-cu-med-biobank-100416731","NCT04706481","Archival of Human Biological Samples in CU-Med Biobank","Inclusion Criteria:\n\n* Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.\n\nExclusion Criteria:\n\n* Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.",{"count":463,"type":23},10000,"99 Years","CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.",[467,468,469,470,29,176,471],"Healthy","Cancer","Heart Diseases","Neurological Diseases or Conditions","Other Disease",[473],"Biobanking","2026-03-11",{"date":476,"type":34},"2026-03-12",{"date":478,"type":34},"2020-01-01",{"date":480,"type":23},"2050-12-01",{"name":482,"class":41},"Chinese University of Hong Kong",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":251,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":493,"conditions":494,"keywords":498,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":42},"100627097","transformative-research-in-diabetic-nephropathy-20-100627097","NCT07444203","Transformative Research in Diabetic Nephropathy 2.0","Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)","TRIDENT 2","Inclusion Criteria:\n\n* Age ≥18 years\n* eGFR ≥10 ml\u002Fmin\u002F1.73 m2 based on the 2021 race-free CKD-EPI equation13\n* Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).\n* Able and willing to provide informed consent for release of one pathology and clinical data abstraction.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Archived biopsy or surgical tissue unavailable for slide preparation.\n* Any local institutional policy that prohibits release of H\\&E slides for research.",{"count":492,"type":23},200,"The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care.\n\nThe main questions this study aims to answer are:\n\n* Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them?\n* Are these kidney tissue patterns linked with how kidney health changes over time?\n\nResearchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines.\n\nParticipants will:\n\nLet researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time",[495,29,496,497],"Diabetic Nephropathies","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2",[499,500,501,502,503,504],"Diabetic nephropathy","Chronic kidney disease","Diabetic kidney disease","Sodium-glucose cotransporter 2 inhibitors","Spatial transcriptomics","Kidney-protective therapy","2026-02-24",{"date":507,"type":34},"2026-03-02",{"date":509,"type":34},"2025-11-12",{"date":511,"type":23},"2028-11-12",{"name":513,"class":41},"University of Pennsylvania",{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":524,"conditions":525,"keywords":530,"overallStatus":316,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":4},"100623204","id-entity-trial--evaluating-serial-t-id-monitoring-100623204","NCT07393594","ID-ENTITY Trial- Evaluating Serial T-ID Monitoring","A Prospective, Multicenter, Observational Study Evaluating Serial T-ID Monitoring for the Prevention of CMV Disease and BK Virus-Associated Nephropathy Following Kidney Transplantation","ID-ENTITY","Inclusion Criteria:\n\n* Participants must meet all the following criteria:\n\n  * Written informed consent and HIPAA authorization obtained prior to any study-related data collection.\n  * Age ≥18 years at the time of enrollment.\n  * Recipient of a kidney transplant, including:\n  * Primary or repeat kidney transplantation\n  * Living-donor or deceased-donor transplantation\n  * At 1 month post-kidney transplant at the time of enrollment.\n  * Receiving maintenance immunosuppressive therapy per institutional standard of care.\n  * Selected by the treating provider to undergo TRAC testing as part of usual post-transplant clinical monitoring.\n\nExclusion Criteria:\n\n* Recipient of a combined organ transplant involving a non-renal solid organ (e.g., kidney-liver, kidney-heart) and\u002For islet cell transplantation.\n* History of prior non-renal solid organ transplantation or islet cell transplantation.\n* Known pregnancy at the time of enrollment.\n* Known active viral infection at enrollment with any of the following:\n* Hepatitis B surface antigen (HBsAg)-positive\n* Hepatitis B virus (HBV) nucleic acid testing (NAT)-positive\n* Human immunodeficiency virus (HIV) infection or HIV NAT-positive\n* \\*Known active BK virus-associated nephropathy (BKVAN) or CMV disease at the time of enrollment.\n* Medical, psychiatric, or social condition that, in the opinion of the Investigator, would interfere with the participant's ability to provide informed consent or comply with study procedures.\n* Concurrent participation in another investigational biomarker study designed to evaluate clinical utility of post-transplant molecular diagnostics.\n\n  * Participants with asymptomatic or low-level viral replication detected during routine clinical monitoring are eligible, provided there is no evidence of established CMV disease or BK virus-associated nephropathy at enrollment.",{"count":523,"type":23},1000,"To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and\u002For biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney transplantation, accounting for the net immune environment (TTV viral load) and allograft injury (donor-derived cell-free DNA, dd-cfDNA).",[29,526,527,528,529],"Kidney Injury","BK Virus Infection","CMV","TTV Virus",[531,532,533,534,535,536,537],"Biomarkers testing","Kidney transplant rejection","T-ID Assay","TRAC Assay cell free DNA","Biopsy","dd-cfDNA","T-ID","2026-02-20",{"date":505,"type":34},{"date":541,"type":23},"2026-03-31",{"date":543,"type":23},"2028-10-30",{"name":545,"class":160},"Transplant Genomics, Inc.",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":18,"minAge":554,"maxAge":555,"enrollmentInfo":556,"targetDuration":4,"studyType":24,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":316,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":4},"100619576","erector-spinae-plane-block-versus-quadratus-lumborum-block-100619576","NCT07346417","Erector Spinae Plane Block Versus Quadratus Lumborum Block","Erector Spinae Plane Block Versus Quadratus Lumborum Block for Post Operative Analgesia in Pediatric Kidney Surgery","ESP-QLB-Peds","Inclusion Criteria:\n\nChildren of both sexes, aged 2-12 years, with ASA physical status I-II scheduled for elective unilateral kidney surgery will be eligible.\n\nExclusion Criteria:\n\n* Infection at the site of needle insertion\n* Allergy to local anesthetics\n* Parental refusal of consent","2 Years","12 Years",{"count":557,"type":23},100,[75],"To compare the efficacy and safety of ultrasound-guided ESPB versus QLB for post-operative analgesia in children undergoing kidney surgery.",[29],[562],"Pediatric- kidney-surgery","2026-01-08",{"date":565,"type":34},"2026-01-16",{"date":567,"type":23},"2025-12-25",{"date":569,"type":23},"2028-03-30",{"name":571,"class":41},"Assiut University",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":127,"enrollmentInfo":578,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":42},"100475706","the-effects-of-the-cf-carrier-state-on-the-kidneys-and-pancreas-100475706","NCT05474417","The Effects of the CF Carrier State on the Kidneys and Pancreas","CF Carrier Inclusion Criteria:\n\n* A CF Carrier identified via genetic testing\n\nControl Inclusion Criteria:\n\n* No previous CF carrier test results\n\nExclusion Criteria:\n\n* CF patient status\n* Unable to speak English\n* Currently pregnant\n* Unable to provide written informed consent\n* Prisoner status\n* Currently taking any medications for the treatment of diabetes",{"count":579,"type":23},1250,"The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.",[582,583,29],"Carrier State","Pancreatic Disease","2026-01-05",{"date":586,"type":34},"2026-01-07",{"date":588,"type":34},"2021-12-20",{"date":590,"type":23},"2026-07",{"name":592,"class":41},"Philip Polgreen",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":400},"100268143","a-prospective-danish-national-registry-of-ptra-in-patients-with-renovascular-hypertension-100268143","NCT02770066","A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension","A Prospective Danish National Registry of Percutaneous Transluminal Renal Angioplasty in Patients With Renovascular Hypertension","DAN-PTRA","Eligibility criteria\n\n1. True resistant hypertension (≥ 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) and uncontrolled blood pressure confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg the patient can be evaluated for renal artery stenosis.\n2. Hypertension and intolerance or side effects of the antihypertensive treatment. Hypertension is confirmed by 24-hour ambulatory blood pressure monitoring. The 24-hour ambulatory blood pressure monitoring is performed after nurse-administered medication and blood pressure measurements are performed hourly. If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg the patient can be evaluated for renal artery stenosis.\n3. Progressive renal insufficiency (a reduction in eGFR \\> 5 ml\u002Fmin\u002F1,73 m2 per year) in patients with bilateral renal artery stenosis or in patients with renal artery stenosis and only one kidney.\n4. Recurrent heart failure\u002Fpulmonary edema and resistant hypertension (≥ 3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses) that may not be attributed to non-compliance, reduced left heart ventricular ejection fraction\u002Fheart valve disease or other obvious explanations (atrial fibrillation, fever, hyperthyroidism etc.). If the average 24-hour ambulatory systolic blood pressure is ≥ 130 mmHg after nurse-administered medication the patient can be evaluated for renal artery stenosis.\n5. Younger patients (\\\u003C 40 years) with hypertension (24-hour ambulatory blood pressure monitoring ≥ 130\u002F80 mmHg after nurse-administered medication )\n\nInclusion Criteria:\n\nAll of the following:\n\n1. At least one of the above eligibility criteria\n2. Duplex doppler ultrasonography or renography investigations consistent with hemodynamically significant renal artery stenosis\n3. CT angiography or renal arteriography with angiographic renal artery stenosis of ≥ 70 % reduction of the luminal diameter in at least one projection\n\nExclusion Criteria:\n\n1. If angiography\u002Farteriography, ultrasonography or renography is consistent with bilateral significant renal artery stenosis and only one side is treated with PTRA\n2. PTRA of a renal artery supplying a kidney which pre-PTRA handles ≤ 10% of the total kidney function (with no blockage of the renin-angiotensin system) and has a kidney size \\\u003C 7 cm (length)",{"count":602,"type":23},160,"A prospective Danish national registry of percutaneous transluminal renal angioplasty (PTRA) in high-risk patients with renal artery stenosis selected on the basis of common national criteria, and with a common follow-up protocol for all three Danish centres offering PTRA",[605,606,607,29],"Renal Artery Obstruction","Hypertension, Renovascular","Cardiovascular Diseases","2025-12-11",{"date":610,"type":34},"2025-12-18",{"date":612,"type":4},"2015-01-01",{"date":614,"type":23},"2035-01",{"name":616,"class":41},"University of Aarhus",{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":624,"enrollmentInfo":625,"targetDuration":627,"studyType":254,"phases":4,"briefSummary":628,"conditions":629,"keywords":638,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":42},"100568077","vorolanib-in-the-second-line-treatment-of-patients-with-unresectable-or-metastatic-renal-cell-carcinoma-100568077","NCT06676527","Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n* Subjects have fully understood and voluntarily signed the informed consent form (ICF);\n* 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;\n* Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;\n* According to RECIST (version 1.1), there are targets that are considered to be observable;\n* The main organs function well.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;\n* Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;\n* A history of severe drug allergy, including but not limited to antibody drugs;\n* Patients with contraindications for immunotherapy restart;\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;\n* Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion\u002Fexclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;\n* Have central nervous system metastases and\u002For cancerous meningitis;\n* Known history of clinically significant liver disease, including those infected with viral hepatitis activity;\n* Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);\n* Patients with any severe and\u002For uncontrolled disease;\n* Renal failure requires hemodialysis or peritoneal dialysis;\n* Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;\n* History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;\n* Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.","80 Years",{"count":626,"type":23},39,"12 Weeks","This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.",[630,631,632,633,141,144,143,29,140,634,635,636,637],"Neoplasms","Kidney Neoplasms","Urologic Neoplasms","Urogenital Neoplasms","Carcinoma","Renal Cell Cancer","Carcinoma, Renal Cell","Antineoplastic Agents",[639,640,641],"observational study","clear cell Renal Cell Carcinoma","TKIs","2025-12-04",{"date":644,"type":34},"2025-12-05",{"date":646,"type":34},"2024-09-01",{"date":648,"type":23},"2026-09-01",{"name":650,"class":41},"Jinling Hospital, China",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":251,"sex":18,"minAge":659,"maxAge":19,"enrollmentInfo":660,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":662,"conditions":663,"keywords":679,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":703,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":42},"100420250","pediatric-hypertension-and-the-renin-angiotensin-system-phrase-100420250","NCT04752293","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)","Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage","PHRASE","INCLUSION CRITERIA: HYPERTENSION COHORT\n\n* 7-18 years of age at time of enrollment\n* Confirmed new diagnosis of primary hypertension: no identifiable secondary cause, referred to hypertension or nephrology clinic\n\n  * Age \\\u003C13 years: BP ≥95th %ile or ≥130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥130\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: HYPERTENSION COHORT\n\n* \\\u003C7 years or \\>18 years of age at time of enrollment\n* BP confirmed as normal or in the elevated BP category based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C95th %ile or \\\u003C130\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C130\u002F80 mmHg\n* A confirmed secondary cause of hypertension\n* Confounding medical condition (heart or kidney disease \\[except hypertension-associated heart changes on echocardiogram or albuminuria\\], vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State\n\nINCLUSION CRITERIA: CONTROL COHORT\n\n* 7-18 years of age at time of enrollment\n* Normal BP based on ≥3 prior office BP measurements on separate days;\n\n  * Age \\\u003C13 years: BP \\\u003C90th %ile or \\\u003C120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP \\\u003C120\u002F80 mmHg\n* Participants and their caregivers must be willing and able to commit to completing the study assessments\n\nEXCLUSION CRITERIA: CONTROL COHORT\n\n* \\\u003C7 or \\>18 years of age at time of enrollment\n* Elevated BP or hypertension, based on ≥3 prior office BP measurements on separate days:\n\n  * Age \\\u003C13 years: BP ≥90th %ile or ≥120\u002F80 mmHg (whichever is lower)\n  * Age ≥13 years: BP ≥120\u002F80 mmHg\n* History of elevated BP or hypertension\n* Current use of BP-lowering medications\n* Confounding medical condition (heart or kidney disease, vascular\u002Finflammatory disease, or diabetes)\n* Inability to complete study assessments\n* Non-English\u002FSpanish speakers\n* Current pregnancy\n* Ward of the State","7 Years",{"count":661,"type":23},125,"Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.",[177,664,665,666,667,29,526,668,669,670,671,672,673,674,675,676,677,678],"Left Ventricular Hypertrophy","Left Ventricular Dysfunction","Left Atrial Dilatation","Left Ventricular Diastolic Dysfunction","Kidney Dysfunction","Sodium Urine High","Blood Pressure Disorders","Uric Acid Retention","Angiotensin Hypertension","Autonomic Dysfunction","Autonomic Imbalance","Pediatric Kidney Disease","Pediatric Obesity","Proteinuria","Albuminuria",[680,681,177,682,683,664,678,684,685,686,687,688,689,690,691,692,693,694,695,696,667,526,697,698,676,699,700,701,702],"High Blood Pressure","Elevated Blood Pressure","Pediatric Hypertension","Target Organ Damage","Uric Acid","Klotho","Fibroblast Growth Factor 23","Renin-Angiotensin-Aldosterone System","Renin-Angiotensin System","Angiotensin-(1-7)","Angiotensin II","Angiotensin-Converting Enzyme 2","Angiotensin-Converting Enzyme","Causal Inference","Causal Mediation Analysis","Sensitivity Analysis","Predictive Analysis","Heart Rate Variability","Sodium","Lifecourse","Kidney Function","Ambulatory Blood Pressure Monitoring","Echocardiogram",{"date":608,"type":34},{"date":705,"type":34},"2021-05-19",{"date":707,"type":23},"2026-12",{"name":709,"class":41},"Wake Forest University Health Sciences",{"id":711,"slug":712,"hasResults":12,"nctId":713,"briefTitle":714,"officialTitle":714,"acronym":4,"eligibilityCriteria":715,"healthyVolunteers":251,"sex":716,"minAge":717,"maxAge":50,"enrollmentInfo":718,"targetDuration":4,"studyType":24,"phases":720,"briefSummary":721,"conditions":722,"keywords":4,"overallStatus":316,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":727,"leadSponsor":729,"locationsCount":4},"100583110","the-effects-of-glucagon-on-renal-regional-blood-flow-in-humans-measured-by-magnetic-resonance-100583110","NCT06872060","The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.","Inclusion Criteria:\n\n* Normal health confirmed through; Interview and Medical examination\n* Normal values with respect to blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function tests, and electrolytes\n* Informed consent\n\nExclusion Criteria:\n\n* Immunosuppressive treatment in the previous 12 months\n* Alcohol abuse\n* Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the principal investigator, may interfere with glucose metabolism\n* Use of lithium\n* Medical treatment that affects insulin secretion or the renin-angiotensin-aldosterone system\n* Liver disease (ALT \\> 2x normal value)\n* Renal impairment (serum creatinine \\> 130 µM and\u002For albuminuria)\n* Individuals with severe claustrophobia\n* Individuals with MR-incompatible foreign bodies\n* Individuals with hypertension","MALE","20 Years",{"count":719,"type":23},10,[75],"This study will investigating the effects of glucagon on renal blood flow in humans using MRI technology. Glucagon, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels. It has been shown to affect renal function, including electrolyte balance and blood flow, especially in conditions like type 2 diabetes where abnormal glucagon levels are common. The study aims to understand how glucagon affects regional blood flow in the kidneys, specifically the cortex and medulla, and whether these effects are mediated by glucagon receptors.\n\nThe study will be conducted on 10 healthy male participants aged 20-60 years. It involves three test days where participants will receive either glucagon, glucagon with a GLP-1 receptor antagonist, or placebo. Blood flow, glomerular filtration rate, and other renal functions will be measured using MRI. The study seeks to clarify whether glucagon's effects on the kidneys are linked to changes in regional blood flow and to determine if these effects are mediated solely by glucagon receptors.",[29],"2025-09-29",{"date":725,"type":34},"2025-10-03",{"date":153,"type":23},{"date":728,"type":23},"2027-11-01",{"name":730,"class":41},"Bispebjerg Hospital"]